Immunomedics price target raised to $44 from $31 at Wells FargoWells Fargo analyst Jim Birchenough raised his price target for Immunomedics to $44 from $31 following meetings with management and stronger confidence in IMMU132 commercial opportunity in TNBC, ER+/HER2- breast cancer, urothelial cancer and other TROP2+ cancers. The analyst reiterates an Outperform rating on the shares.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.